Alkermes Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Balanced Scorecard for Deeper Strategic Insight
This Alkermes Balanced Scorecard Analysis gives you a structured view of the company's financial, customer, internal process, and learning and growth priorities. This page already shows a real preview of the actual report content, so you can review the style and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Pipeline Clarity
A Balanced Scorecard helps Alkermes tie its 2 marketed drugs, VIVITROL and ARISTADA, to its CNS pipeline, so leaders can track how Phase 2 and Phase 3 data turn into revenue. In fiscal 2025, Alkermes reported about $1.6 billion in revenue, showing why launch readiness and reimbursement matter as much as science. That one view makes pipeline risk, approval timing, and revenue conversion easier to manage.
Adherence Metrics
For Alkermes, adherence metrics like persistence, refill rate, and discontinuation are more useful than sales alone because Aristada offers 1-, 2-, 3-, and 6-month dosing, so missed refills are easy to spot. In schizophrenia, nonadherence is linked to higher relapse and hospitalization risk, so these metrics act as real-world benefit proxies. They also show whether the customer keeps therapy on board, not just starts it.
Access Focus
Alkermes should track access as closely as clinical data: in FY2025, the company's revenue was about $1.4 billion, so payer reach still drives real value. A balanced scorecard should flag formulary wins, prior-authorization delay, and net price realization, because a drug with strong efficacy still fails if patients cannot start it. The team's job is simple: turn approval into filled prescriptions, fast.
Quality Control
For Alkermes, quality control is a scorecard driver because injectable and formulation-heavy CNS products depend on batch release success, low deviation rates, and tight yield control. Process reliability protects supply continuity, which supports revenue stability and keeps prescriber confidence high. In 2025, that matters even more in a portfolio where one failed lot can disrupt patient access and margin.
Portfolio Balance
Portfolio balance shows whether Alkermes can offset its revenue concentration with breadth across schizophrenia, bipolar I disorder, and multiple sclerosis. In 2025, that matters because the Company depends on a small set of marketed medicines, so even one weaker product can move results fast. It also pushes capital toward programs that can replace or extend value, instead of spreading spend too thin.
- Tracks mix risk across core franchises
- Improves capital discipline by program
Alkermes scorecard: turning clinical wins into revenue
Benefits in Alkermes balanced scorecard center on turning clinical proof into paid use: in FY2025, about $1.4 billion in revenue shows why access, adherence, and refill rates matter. With VIVITROL and ARISTADA, the scorecard helps spot where patients stay on therapy and where payers slow starts. It also links launch wins to cash flow.
| FY2025 signal | Benefit |
|---|---|
| $1.4B revenue | Shows conversion |
| Refill/persistence | Shows patient stay |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Binary Regulatory Risk
Binary regulatory risk makes the balanced scorecard look safer than it is for Alkermes plc, because one FDA or EMA decision can outweigh months of KPI gains. A single Phase 3 miss or label restriction can hit the whole pipeline at once, so the scorecard can overstate control in a business where approval odds, not just execution, drive value. For a company with only a small set of marketed assets, one adverse readout can shift revenue, launch timing, and sentiment far more than a strong quarter can fix.
Noisy CNS Outcomes
Noisy CNS outcomes make Alkermes harder to compare across schizophrenia and bipolar studies because key tools differ: PANSS has 30 items, while MADRS has 10, and both rely on site scoring and patient reporting. Relapse timing and functional endpoints also vary by protocol, so a win in one trial can look weaker in another. That noise can blur the read-through on LYBALVI and other CNS assets.
Slow Data Cycles
For Alkermes, slow data cycles can hide a move until the next quarterly report, so a 90-day lag can make revenue, prescription, and trial trends look older than they are. Clinical readouts often come in batches, and by the time a metric shifts, the real trend may already be 2-3 months old. That matters when one late update can move a stock that still has to digest full-year 2025 results.
Heavy Setup
Heavy setup is a real drawback for Alkermes because a useful scorecard needs clean 2025 data across R&D, manufacturing, market access, and sales. That means more reporting work, more system links, and more chances for dashboard noise when figures do not tie out. Alkermes reported $1.53 billion in 2025 revenue, so even small data errors can distort how each function looks.
Benchmark Limits
Benchmark limits matter because Alkermes is not a broad, diversified pharma peer. Its mix is narrower, so direct comparisons can distort readouts when rivals have different product portfolios, pipeline stages, and patent-expiry timing. That makes peer scorecards useful for context, but weak as a stand-alone measure of operating strength.
Alkermes' Small 2025 Base Raises Big Trial Risk
Alkermes has a narrow 2025 base, with $1.53 billion revenue, so one FDA or Phase 3 miss can swing the whole Balanced Scorecard more than routine KPI gains can offset.
CNS readouts stay noisy because PANSS has 30 items and MADRS has 10, so site scoring and patient reports can blur trial quality across assets.
That makes benchmarking weak too, since rivals have broader portfolios and different patent clocks, while 90-day reporting lags can leave 2025 trends stale.
| Drawback | 2025 data point | Why it matters |
|---|---|---|
| Concentration risk | $1.53 billion revenue | One setback can move results fast |
| Trial noise | PANSS 30; MADRS 10 | Harder to compare outcomes |
| Slow visibility | About 90-day lag | Scorecard can trail reality |
Preview Before You Purchase
Alkermes Reference Sources
This is the actual Alkermes Balanced Scorecard analysis document you'll receive upon purchase – no surprises, just a professional, ready-to-use report. The preview below is taken directly from the full document, so what you see is exactly what you get. Once purchased, you'll unlock the complete Balanced Scorecard analysis in full detail.
Frequently Asked Questions
It shows whether Alkermes is turning CNS science into durable commercial value. A strong scorecard links Phase 2 and Phase 3 milestones, prescription growth for Vivitrol, Aristada, and Lybalvi, and operating cash flow. The best versions also track 90-day persistence and reimbursement coverage, because those indicators show whether patients can stay on therapy.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.